A Genetic Basis for Luminal and Basal-Type Breast Cancer by Hollestelle, A. (Antoinette)
STELLINGEN 
Behorende bij het proefschrift 
A Genetic Basis for Luminal and Basal-Type Breast Cancer 
 
1. The involvement of distinct biological pathways with genetic and epigenetic 
inactivation of E-cadherin challenges the paradigm that gene mutation and 
promoter methylation are two means to the same end in inactivating tumor 
suppressor genes (this thesis). 
 
2. The non-causality of E-cadherin loss for the spindle cell morphology of breast 
cancer cell lines suggests that loss of E-cadherin is not a hallmark of epithelial to 
mesenchymal transition (this thesis). 
 
3. Loss of E-cadherin protein expression is not a good marker to classify lobular breast 
cancers (this thesis). Analysis of p120ctn expression in routine diagnostics should be 
considered instead. 
 
4. α-Catenin is a putative new tumor suppressor gene (this thesis). 
 
5. Luminal and basal-type breast cancers associate with distinct gene mutation 
profiles (this thesis). 
 
6. It is the infrequently mutated gene “hills” and not the commonly mutated gene 
“mountains” that dominate the cancer genome landscape. The large number of 
“hills” actually reflects alterations in a much smaller number of cell signaling 
pathways (Wood et al., Science 2007;318:1108-13). 
 
7. A “promiscuous” polygenic model for breast cancer in which multiple common low-
risk variants act multiplicative explains a high breast cancer incidence in the 
population and suggests that the majority of breast cancers are, in fact, hereditary. 
 
8. An alternative approach to the direct application of gene signatures is the 
translation of such profiles to protein expression characteristics, using immu-
nohistochemistry on formalin-fixed paraffin-embedded tissue (Rakha et al., 
Histopathology 2008;52:67-81). 
 
9. The terms “lobular” and “ductal” used to designate the two major pathological 
subtypes of breast cancer are misleading, because they raise the misconception that 
the pathological subtypes of breast cancer are determined by their cell of origin 
instead of their cytological and architectural features. 
 
10. The observation that shRNA suppression of PTEN in BT474 breast cancer cells 
induces resistance to trastuzumab (Berns et al., Cancer Cell 2007;12:395-402) 
suggests that the K111N mutation in the p85 binding domain of PIK3CA is not 
relevant for trastuzumab resistance. 
 
11. More can be less, if enough is enough (from “This Much” by Grace Tjon A Fat, 
songwriter) 
